Below you'll find a list of all posts that have been categorized as “Research News”
The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application for tofersen, a drug in development by Biogen for treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) – and granted priority review for the application. …
New results from the Phase 3 clinical trial of tofersen, a drug in development by Biogen, have shown promise in treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). According to the 12-month data, earlier initiation of treatment with …
As connecting fibers between motor neurons, axons help deliver vital messages between the brain and the spinal cord. For people living with ALS, deteriorating axons cause that connection to break, contributing to paralysis and death. Early research on NU-9, an …
The 40+ research scientists at the Les Turner ALS Center at Northwestern Medicine investigate a wide range of biologic mechanisms in ALS basic research. We are pleased to announce the recent publication of three new research papers from some of …
The Les Turner ALS Foundation is excited to announce nearly $1 million to be funded in 2022 for new research grants and clinic and endowment support to the Les Turner ALS Center at Northwestern Medicine! These discoveries would not have …
February 11, 2022 Dear NINDS, As we set our sights on shaping the strategic future of ALS research, we thank you for the opportunity to identify key research and priorities at NIH and beyond. We also recognize …
By Marta Figueiredo PhD | November 18, 2021 Recent findings and ongoing efforts to more fully understand the underlying molecular mechanisms of amyotrophic lateral sclerosis (ALS), and to identify new and better ways of helping patients were discussed at the 11th Annual Les Turner Symposium …
BY MELISSA ROHMAN ON NOV 4, 2021 Northwestern scientists and clinicians demonstrated their continued commitment to advancing knowledge and therapies for amyotrophic lateral sclerosis (ALS) during the 11th annual Les Turner Symposium on ALS. The virtual, daylong symposium featured scientific presentations highlighting the molecular …
The following note is being passed along from the Board of Directors of the International Alliance of ALS/MND Associations… The Board of Directors of the International Alliance of ALS/MND Associations is pleased to provide information for Member Associations in the …
On September 15, Amylyx Pharmaceuticals announced its intention to submit a New Drug Application to the FDA for AMX0035 for the treatment of ALS. If the New Drug Application is successful, AMX0035 would be only the third drug approved by …
